Comparison of Two Dosing Regimens of Temozolomide in Patients With Progressive or Recurrent Glioblastoma

Prof. Dr. Wolfgang Wick105 enrolled

Overview

For patients with progressive or recurrent glioblastoma there is no standard therapy. One strategy is re-exposure to temozolomide in a higher dose. This increase in dosing can be done by 2 regimens. Aim of this study is to compare these 2 dosing regimens concerning toxicity. In study arm A patients receive temozolomide for one week, followed by a week without temozolomide. In study arm B patients receive temozolomide for three weeks, followed by a week without temozolomide. The regimen that is less toxic will be selected for further evaluations.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

105

Conditions

Glioblastoma

Interventions

Temozolomide in both armsDRUG

initial dose 120 mg/m2 in arm A

Temozolomide in both armsDRUG

initial dose 80 mg/m2 in arm B

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Progressive or recurrent glioblastoma documented by MRI no earlier than 180 days after first surgery for glioblastoma and no earlier than 90 days after completion of radiotherapy. * Histological diagnosis of glioblastoma * Tissue available for the determination of MGMT promoter methylation in the primary tumor or from the recurrent tumor if a patient undergoes a surgical procedure at recurrence prior to study entry. * Prior treatment with temozolomide administered concomitantly with radiotherapy and at least for two cycles (5/28) as an adjuvant treatment * Informed consent * Age 18-80 years * Karnofsky performance score \> 50% * Neutrophil counts \> 1 500/µl * Platelet counts \> 100 000/µl * Hemoglobin \> 10 g/dl * Serum creatinin \< 1.5-fold upper normal range * ASAT or ALAT \< 3-fold upper normal range unless attributed to anticonvulsants * Alkaline phosphatase \< 3-fold upper normal range * Women with childbearing potential must have a negative serum pregnancy test ≤14 days prior to study enrollment * Willingness to apply contraception according to local requirements (as stated in patient information) Exclusion Criteria: * Progressive or recurrent glioblastoma documented by MRI earlier than 180 days after first surgery for glioblastoma and earlier than 90 days after completion of radiotherapy. * Treatment with any chemotherapy other than temozolomide according to the schedule of the EORTC NCIC trial (Stupp et al. N Engl J Med 2005;352:987-996) except that an adjuvant starting dose of 200 mg/m2 and more than 6 cycles of adjuvant temozolomide are allowed * Prior systemic or local treatment with DNA-damaging agents, tyrosine kinase inhibitors or anti-angiogenic agents for any cancer * Allergy to or other intolerability of temozolomide * Unable to undergo MRI * Past medical history of diseases with poor prognosis, e.g. severe coronary heart disease, severe diabetes, immune deficiency, residual deficits after stroke, severe mental retardation * HIV infection * Pregnancy * Breast feeding * Treatment within in any other clinical trial parallel to the treatment phase of the current study

Locations (16)

Landesnervenklinik Wagner-Jauregg

Linz, Austria

Medical University Vienna, Department of Internal Medicine I

Vienna, Austria

Outcomes

Primary Outcomes

Median time to treatment failure. Treatment failure is reached (i) upon tumor progression as outlined in protocol (ii) if treatment has to be terminated due to toxicity or (iii) if the patient dies for any reason.

Time frame: up to one year

Secondary Outcomes

progression free survival

Time frame: up to two years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.